Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)

Trial Profile

Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)

Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Providence Health & Services
  • Most Recent Events

    • 25 Jun 2018 Planned number of patients changed from 6 to 18.
    • 23 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 27 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 15 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top